Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has been given a consensus rating of “Buy” by the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation and two have given a strong buy r
Source link
Oops! You don’t have access to this content. In order to view it you must purchase the subscription. For more information contact us on the Live Chat. Username or E-mail Password Remember Me Forgot Password The post Market Speculator Part-Time | Swing Trade Report appeared first on Bulls on Wall Street. Source link
Hi ASFers, I wanted to begin a thread on SDI – Southern Dental Industires to discuss this stock and get your opinions. I do not hold any stock in this company but i have it on my watch list. Its been a real dog of a share over the past four years and its share…
All working Canadians aged 18 to 65 who earn over $3,500 annually must contribute to the Canada Pension Plan (CPP) retirement pension. Contributions past 65 are voluntary for users working until 70. The CPP pegs the standard retirement age at 65, but you can start payments at 60. There’s a delay option, too, although very…
This content is for members only Source link
Hi guys, very late 11th hour for this, but I just got refered to a cracker of an IPO Montezuma Mining, its 2 points of difference are its management (some of the best geologists in the business) and the projects they've pegged. See below for extracts from IPO Shares = 14m vendor + seed 22.5m…
Hims & Hers Health, Inc. (NYSE: HIMS) experienced a significant increase in its stock price on August 5,… This article 📊 Hims & Hers Health hits 1.9M subscribers! 43% growth year-over-year! 🏆 appeared first on Guerilla Stock Trading. Source link